sotorasib + Anti PD-1/L1 + Midazolam
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS p.G12C Mutant Advanced Solid Tumors
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Trial Timeline
Aug 27, 2018 → May 30, 2026
NCT ID
NCT03600883About sotorasib + Anti PD-1/L1 + Midazolam
sotorasib + Anti PD-1/L1 + Midazolam is a phase 1/2 stage product being developed by Amgen for KRAS p.G12C Mutant Advanced Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT03600883. Target conditions include KRAS p.G12C Mutant Advanced Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in KRAS p.G12C Mutant Advanced Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03600883 | Phase 1/2 | Active |
Competing Products
20 competing products in KRAS p.G12C Mutant Advanced Solid Tumors